Enhanced tamoxifen bioavailability after oral administration of tamoxifen in rats pretreated with naringin

Archives of Pharmacal Research

Volumn 31, Issue 12, 2008, Pages 1631-1636

  Choi, Jun Shik ^a   Kang, Keon Wook ^a  

^a Chosun University   (South Korea)

Author keywords

4 Hydroxytamoxifen; Bioavailability; Naringin; Pharmacokinetics; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; AURANTIIN; CYTOCHROME P450 3A4; TAMOXIFEN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; FEMALE; NONHUMAN; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FLAVANONES; HALF-LIFE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN;

EID: 58449111594     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-001-2161-7     Document Type: Article

References (30)

1. D. G.. Bailey J. M. O. Arnold J. D. Spence 1998 Grapefruit juice-drug interactions Br. J. Clin. Pharmacol. 46 101 110
2. Buchanan, C. M., Buchanan, N. L., Edgar, K. J., Little, J. L., Malcolm, M. O., Ruble, K. M., Wacher, V. J., and Wempe, M. F., Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen-hydroxybutenyl-beta- cyclodextrin formulations. J. Pharm. Sci., in press (2006).
3. M. T. Buckley K. L. Goa 1989 Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use Clin. Pharmacokin. 37 451 490
4. H. K. Crewe S. W. Ellis M. S. Lennard G. T. Tucker 1997 Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes Biochem. Pharmacol. 53 171 178
5. P. C. Daniel J. Gaskell H. Bishop C. Campbell R. Nicholson 1981 Determination of tamoxifen and biologically active metabolites in human breast tumour and plasma Eur. J. Cancer Clin. Oncol. 17 1183 1189
6. R. A. Dixon C. Steele 1999 Flavonoids and isoflavonoids-gold mine for metabolic engineering Trends Plant Sci. 4 394 400
7. V. A. Eagling L. Profit D. J. Back 1999 Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components Br. J. Clin. Pharmacol. 48 543 552
8. T. Fornander A. C. Hellstrom B. Moberger 1993 Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer J. Nat. Cancer Inst. 85 1850 1855
9. K. M. Fried I. W. Wainer 1994 Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography J. Chromatogr. B. Biomed. Appl. 655 261 268
10. T. W. Gant C. K. O'Connor R. Corbitt U. Thorgeirsson S. S. Thorgeirsson 1995 In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys Toxicol. Appl. Pharmacol. 133 269 276
11. M. M. Gottesman I. Pastan 1993 Biochemistry of multidrug resistance mediated by the multidrug transporter Annu. Rev. Biochem. 62 385 427
12. P. C. Ho D. J. Saville P. C. Coville S. Wanwimolruk 2000 Content of CYP3A4 inhibitors, naringin, naringenin and bergapten in grapefruit and grapefruit juice products Pharmaceut. Acta. Helv. 74 379 385
13. P. C. Ho D. J. Saville S. Wanwimolruk 2001 Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds J. Pharm. Pharm. Sci. 4 217 227
14. F. Jacolot I. Simon I. Dreano P. Beaune C. Riche F. Berthou 1991 Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes Biochem. Pharmacol. 41 1911 1919
15. I. A. Jaiyesimi A. U. Buzdar D. A. Decker G. N. Hortobagyi 1995 Use of tamoxifen for breast cancer: twenty-eight years later J. Clin. Oncol. 13 513 529
16. V. C. Jordan M. M. Collins L. Rowsby G. Prestwich 1977 A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity J. Endocrinol. 75 305 316
17. D. H. Kim E. A. Jung I. S. Sohng J. A. Han T. H. Kim M. J. Han 1998 Intestinal bacterial metabolism of flavonoids and its relation to some biological activities Arch. Pharm. Res. 21 17 23
18. C. Mani H. V. Gelboin S. S. Park R. Pearce A. Parkinson D. Kupfer 1993 Metabolism of the antimammary cancer antiestrogenic agent tamoxifen, I. Cytochrome P450-catalysed N-demethylation and 4-hydroxylation Drug Metab. Dispos. 21 645 656
19. C. R. Meier H. Jick 1998 Tamoxifen and risk of idiopathic venous thromboembolism Br. J. Clin. Pharmacol. 45 608 612
20. R. J. Nijveldt E. van Nood D. E. C. van Hoorn P. G. Boelens K. van Norren P. A. M. van Leeuwen 2001 Flavonoids: a review of probable mechanisms of action and potential applications Am. J. Clin. Nutr. 74 418 425
21. T. J. Powles 1992 The case for clinical trials of tamoxifen for prevention of breast cancer Lancet 340 1145 1147
22. U. S. Rao R. L. Fine G. A. Scarborough 1994 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein Biochem. Pharmacol. 48 287 292
23. S. C. Shin J. S. Choi X. Li 2006 Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats Int. J. Pharm. 313 144 149
24. R. Stone 1992 NIH fends off critics of tamoxifen study Science 258 734
25. H. Takanaga A. Ohnishi H. Matsuo Y. Sawada 1998 Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells Biol. Pharm. Bull. 21 1062 1066
26. F. Thiebaut T. Tsuruo H. Hamada M. M. Cottesman I. Pastan M. C. Willingham 1987 Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc. Natl. Acad. Sci. U.S.A. 84 7735 7738
27. V. H. Wacher J. A. Silverman Y. Zhang L. Z. Benet 1998 Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics J. Pharm. Sci. 87 1322 1330
28. P. B. Watkins 1996 The barrier function of CYP3A4 and P-glycoprotein in the small bowel Adv. Drug Deliv. Rev. 27 161 170
29. C. H. Yeum J. S. Choi 2006 Effect of naringin pretreatment on bioavailability of verapamil in rabbits Arch. Pharm. Res. 29 102 107
30. H. Zhang C. W. Wong P. G. Coville S. Wanwimolruk 2000 Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats Drug Metabol. Drug Interact. 17 351 363